Immunotherapy Advances : Impact Factor & More
eISSN: 2732-4303
Open AccessShare this on:
Key Metrics
SJR 
Q4Mathematics (all)
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on Immunotherapy Advances
Immunotherapy Advances Journal Specifications
Indexed in the following public directories
Web of Science 
DOAJ
| Overview | |
| Publisher | Oxford University Press |
| Language | English |
| Article Processing Charges | GBP 2100 |
| Publication Time | 7 |
| Editorial Review Process | Anonymous peer review |
| General Details | |
| Publication Details | |
| Publication Time | 7 |
| Waiver Policy | Visit website |
| Editorial Review Detail | |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY, CC BY-NC |
| OA statement | Visit website |
View less
Planning to publish in Immunotherapy Advances ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Immunotherapy Advances
Chimeric CD3ζ chains containing CD28 signalling motifs enhance antigen-specific IL-2 production and expansion of human TCR-engineered T cells in vitro
- 1 Apr 2026
- Immunotherapy Advances
PD-1 inhibitor-induced rheumatic, endocrine, and sarcoidosis-like immune-related adverse events in metastatic melanoma are associated with improved survival and lower corticosteroid exposure.
- 21 Feb 2026
- Immunotherapy advances
Comprehensive spatial and immune profiling of metastatic mismatch repair–deficient colorectal cancer reveals response to immunotherapy
- 9 Jan 2026
- Immunotherapy Advances
Overall survival by baseline and on-treatment systemic immune-inflammation index in patients with advanced cancer receiving immune checkpoint inhibitors: a large single-centre cohort study.
- 31 Dec 2025
- Immunotherapy advances
Neuraminidase A controls pneumococcal recognition and fate: deficiency enhances immune sensing and intracellular survival, while treatment promotes phagocytic clearance.
- 31 Dec 2025
- Immunotherapy Advances
Turning the tide: harnessing vaccines and viruses to fight cancer
- 23 Dec 2025
- Immunotherapy Advances
Chimeric CD3ζ chains containing CD28 signalling motifs enhance antigen-specific IL-2 production and expansion of human TCR-engineered T cells in vitro
- 1 Apr 2026
- Immunotherapy Advances
PD-1 inhibitor-induced rheumatic, endocrine, and sarcoidosis-like immune-related adverse events in metastatic melanoma are associated with improved survival and lower corticosteroid exposure.
- 21 Feb 2026
- Immunotherapy advances
Comprehensive spatial and immune profiling of metastatic mismatch repair–deficient colorectal cancer reveals response to immunotherapy
- 9 Jan 2026
- Immunotherapy Advances
Overall survival by baseline and on-treatment systemic immune-inflammation index in patients with advanced cancer receiving immune checkpoint inhibitors: a large single-centre cohort study.
- 31 Dec 2025
- Immunotherapy advances
Neuraminidase A controls pneumococcal recognition and fate: deficiency enhances immune sensing and intracellular survival, while treatment promotes phagocytic clearance.
- 31 Dec 2025
- Immunotherapy Advances
Turning the tide: harnessing vaccines and viruses to fight cancer
- 23 Dec 2025
- Immunotherapy Advances
FAQs on Immunotherapy Advances
How many articles did Immunotherapy Advances publish last year? 
What is the SJR for Immunotherapy Advances?
Who is the publisher of Immunotherapy Advances?
Check if your manuscript is a good match for
undefined
Upload your manuscript to get recommendations of journals
that have published papers similar to your manuscript
Drag and drop your file here
We accept manuscripts in English. File format: .doc and .docx | Maximum size: 10 MB | Word count: 200-300,000 words | File length: less than 100 pages
Do not have a manuscript right now? Use an abstract or summary
Your document is 100% secure & confidential We use 256-bit encryption for total security and
ISO/IEC 27001:2013 Certified
What all does the report include
01. Degree of Match
02. Common Topics
03. Additional
Recommendations
Recommendations